Abstract 1205TiP
Background
Extrapulmonary neuroendocrine carcinoma has a poor prognosis with a median survival of about 1 year. The current standard first-line treatment for extrapulmonary neuroendocrine carcinoma is etoposide combined with cisplatin (EP) or etoposide combined with carboplatin (EC). Camrelizumab (anti-PD-1 antibody) and apatinib (VEGFR2-TKI) have shown definite antitumor effects in a variety of solid tumors. The aim of this study is to evaluate the efficacy and safety of camrelizumab combined with EP/EC chemotherapy, followed by camrelizumab plus apatinib as first-line treatment for advanced or metastatic extrapulmonary neuroendocrine carcinoma.
Trial design
This prospective, single-arm, multicenter study plans to enroll 30 patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma who have not been systematically treated. Enrolled patients will receive 4-6 cycles of EP (etoposide 100mg/m2 d1-3 iv+ cisplatin 25mg/m2 d1-3 iv, repeated every 21 days) or EC (etoposide 100mg/m2 d1-3 iv+ carboplatin AUC=5 d1 iv, repeated every 21 days) in combination with camrelizumab (200mg iv d1, repeated every 21 days). Patients with remission or stable disease will receive camrelizumab (200mg, d1, iv, repeated every 21 days) plus apatinib (250mg orally, once daily) as maintainance therapy until disease progression or unacceptable toxicity. Camrelizumab will be administered for a total of 2 years, and patients with stable or remission disease will continue apatinib treatment until disease progression. The primary endpoint of this study is objective response rate (ORR), while secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR) and safety.
Clinical trial identification
NCT05142865.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1785P - Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Presenter: Alberto Dalla Volta
Session: Poster session 14
1787P - Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Presenter: Hoda Abdel-Aty
Session: Poster session 14
1789P - Low- and high-volume disease in mHSPC: From CHAARTED to PSMA PET
Presenter: Lena Unterrainer
Session: Poster session 14
1790P - Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK
Presenter: Joanna Dodkins
Session: Poster session 14
1791P - Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Presenter: Marta Garcia De Herreros
Session: Poster session 14
1792P - Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 14
1793P - PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14